AIDS / HIV

  1. Home
  2. Health
  3. AIDS / HIV

Rebetron (Ribavirin+Interferon alfa)

By Mark Cichocki, R.N., About.com

Updated: November 30, 2008

About.com Health's Disease and Condition content is reviewed by the Medical Review Board

What is Rebetron?:

  • Rebetron is a combination of intron (an alfa interferon) and ribavirin (an antiviral drug).

How is Rebetron Administered?:

  • Intron is administered as a subcutaneous injection (just beneath the skin) in doses of 3 million units three times per week.
  • Ribavirin is a capsule taken in doses of 1000 to 1200mg per day based on body weight.

How Effective is Rebetron?:

  • Ribavirin alone is not effective in suppressing hepatitis C virus counts and must be used in combination with interferon.
  • Approximately 30-40% of patients will have a sustained response after a course of rebetron treatment.

What are the Side Effects of Rebetron?:

  • Side effects include those of interferon and ribavirin.
  • Side effects of ribavirin include:
    • itching
    • rash
    • stomach pain
    • diarrhea
  • Anemia (decrease red blood cells count). The most common symptoms of anemia include:
    • fatigue
    • shortness of breath
  • Serious birth defects - for this reason, men and women with reproductive potential must practice dual measures of birth control during treatment and for 6 months after stopping treatment.

For More Information:

To find more information on Rebetron try About'com's Drug Finder.

Explore AIDS / HIV

About.com Special Features

Do I Have Allergies?

Are your symptoms merely irritating, or could they be a sign of allergies? More >

Preventing Headaches

The best way to treat a headache is to prevent it. Learn how. More >

We comply with the HONcode standard for trustworthy health information: verify here.

AIDS / HIV

  1. Home
  2. Health
  3. AIDS / HIV
  4. Medication Information
  5. Hepatitis Medications
  6. Rebetron - Hepatitis - Hepatitis Medication - Ribavirin - Interferon-alfa - Hepatitis C

©2009 About.com, a part of The New York Times Company.

All rights reserved.